Evidence map›Paper›PMID 42198718›Full record

ArticleViruses2026

Chronic HDV Infection Shows Higher HBsAg Isoform Levels than HBV Infection, Paralleling HDV Replicative Activity.

Stefano D'Anna, Lorenzo Piermatteo, Alessia Magnapera, Ilaria Grossi, Caterina Tramontozzi, Antonella Olivero, Leonardo Duca, Giulia Torre, Elisabetta Teti, Andrea Di Lorenzo and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Stefano D'AnnaDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0003-9334-8582
Lorenzo PiermatteoDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-3500-0858
Alessia MagnaperaDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Ilaria GrossiDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Caterina TramontozziDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Antonella OliveroDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0003-0327-3875
Leonardo DucaDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0009-0008-2970-2037
Giulia TorreDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.
Elisabetta TetiDepartment of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, 00133 Rome, Italy.
Andrea Di LorenzoDepartment of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, 00133 Rome, Italy.ORCID 0009-0008-1772-196X
Vincenzo MalagninoDepartment of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-6561-5298
Marco IannettaDepartment of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0002-6938-8627
Sandro GrelliDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0003-1028-3203
Pierpaolo PabaVirology Unit, Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0009-0003-1168-4946
Ada BertoliDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Francesca Ceccherini-SilbersteinDepartment of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Leonardo BaiocchiHepatology Unit, Policlinico Tor Vergata, 00133 Rome, Italy.
Simona FranciosoHepatology Unit, Policlinico Tor Vergata, 00133 Rome, Italy.
Ilaria LenciHepatology Unit, Policlinico Tor Vergata, 00133 Rome, Italy.ORCID 0000-0001-5704-9890
Michele MilellaDepartment of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari "Aldo Moro", 70121 Bari, Italy.
Annalisa SaracinoDepartment of Biomedical Sciences and Human Oncology, Clinic of Infectious Diseases, University of Bari "Aldo Moro", 70121 Bari, Italy.
Alessia CiancioDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-9026-6181
Giuseppina BrancaccioDepartment of Life Sciences, Health and Health Professions, Università degli Studi di Roma Link Campus University, 00165 Rome, Italy.
Loredana SarmatiDepartment of Systems Medicine, Infectious Disease Clinic, Tor Vergata University, 00133 Rome, Italy.ORCID 0000-0003-1452-0333
Pietro LamperticoDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-1026-7476
Mario RizzettoDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.
Gian Paolo CavigliaDepartment of Medical Sciences, University of Turin, 10126 Turin, Italy.ORCID 0000-0002-0529-9481
Romina SalpiniDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.ORCID 0000-0002-2488-2082
Valentina SvicherDepartment of Biology, University of Rome Tor Vergata, 00133 Rome, Italy.

Funding

Innovative Health Initiative 101194735Ministero dell'università e della ricerca 2022X2KWRKMinistero dell'università e della ricerca P2022WEXP2
6 · The paper itself

Abstract

BACKGROUND &

aimThe entry of Hepatitis D Virus (HDV) depends on HBV surface proteins (HBsAg) composed of three isoforms: large-, middle, and small HBsAg. Here, we investigate the levels of total HBsAg and HBsAg isoforms and their correlations with HDV-RNA, HBcrAg, and transaminases in the setting of untreated chronic hepatitis D (CHD).

methodsThis study includes 316 HBeAg-negative patients: 192 CHD and 124 with chronic hepatitis B (CHB) as a control group. HBsAg isoforms were quantified by ad hoc-designed ELISAs.

resultsThe composition of HBsAg isoforms varied between the two groups of patients, with remarkably higher small HBsAg, middle-HBsAg, and large HBsAg in CHD than in CHB. This data was confirmed by multivariable analysis (

conclusionsCHD is characterized by a more elevated HBsAg isoform production, paralleling HDV-RNA and HBcrAg release. This may suggest a preferential recruitment of HBsAg isoforms in HDV virions at the expense of HBV virions. The association of HBsAg isoforms with higher ALT also suggests their potential contribution in supporting HDV-induced pro-inflammatory stimuli.

Indexed as

Hepatitis B, ChronicHepatitis B Surface AntigensHepatitis B virusHepatitis D, ChronicHepatitis Delta VirusVirus ReplicationAdultEnzyme-Linked Immunosorbent AssayFemaleHepatitis B Core AntigensHumansMaleMiddle AgedProtein IsoformsRNA, ViralHepatitis B Core AntigensHepatitis B Surface AntigensProtein IsoformsRNA, Viralchronic hepatitis DHBcrAgHBsAg isoformsHDV-RNAtotal HBsAg

Identifiers

PMID42198718
PMCPMC13211560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.